BfR Warns on Infant Vitamin D Overdosing, Reaffirms Prudence for Senior Supplementation

Berlin, Germany — 07 August 2026

The German Federal Institute for Risk Assessment (BfR) has issued a critical warning regarding excessive Vitamin D intake in infants, specifically highlighting the risk of hypervitaminosis D. The institute reported that over-supplementation can lead to adverse health outcomes in young children. The BfR has also reiterated its stance that healthy older individuals generally meet their nutritional requirements through a balanced diet, making routine micronutrient supplementation largely unnecessary.

For infants, the BfR's concern centres on the potential for acute toxicity from high-dose Vitamin D products. While Vitamin D is crucial for bone health, the margin between beneficial and harmful doses in infants is narrow. Manufacturers and brand owners producing infant-specific Vitamin D supplements must scrutinise their product formulations, recommended dosages, and warning labels. Instances of hypervitaminosis D are often linked to misinterpretation of dosage instructions or the use of adult-strength products in infants, inadvertently exceeding safe intake levels.

Regarding the elderly, the BfR's consistent advice is that supplemental micronutrients are typically not required for those maintaining a balanced diet. This position challenges the broad marketing narratives often employed by supplement brands targeting the 'healthy ageing' demographic. The institute advises that supplementation should only occur in cases of medically confirmed deficiencies, under professional guidance. This stance impacts product development and marketing strategies, demanding more specific targeting and evidence-based claims rather than general health benefits.

What this means for Germany

German manufacturers and brand owners must immediately review all Vitamin D products marketed for infants, ensuring precise dosing mechanisms and unequivocal labelling to prevent hypervitaminosis, with a compliance focus before end of Q3 2026. For the senior market, 'healthy ageing' claims for micronutrient supplements now require stronger substantiation, aligning with the BfR's position on dietary sufficiency for healthy individuals. This will necessitate reformulation or revised marketing for products lacking targeted medical justification. Procurement teams should anticipate potential demand shifts away from general senior formulations towards more specific, clinically indicated products, impacting inventory and R&D pipelines for new product launches in 2027.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.